Amarin Stock Looks Attractive Despite U.S. Litigations

Summary

• AMRN shares are up almost 30% last month, likely due in part to AMRN's success in keeping generics to 11% market share and the imminent European launch.
• AMRN share price is still near its lows since it reported its REDUCE-IT data in 2018.
• As the Nevada ANDA litigation weaves thru a 2nd appeal from a last-ditch investor-initiated effort to save AMRN's case, a generic company and others have filed anti-trust lawsuits against AMRN.
• AMRN has a chance at winning its Delaware patent infringement lawsuit against Hikma and Health Net.
• There were a number of updates last month in the pending AMRN v. generic and relevant litigations, in AMRN's favor.

smartstock/iStock via Getty Images

Amarin (NASDAQ:AMRN) currently has one therapeutic asset, its approved cardiovascular drug Vascepa. It is in a series of lawsuits with generic manufacturers, who are now on the market with generic versions of Vascepa (See FIG. 1). AMRN investors have needed to assess these litigations, as they

Analyst’s Disclosure:I/we have a beneficial long position in the shares of AMRN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.